Search
FDA Grants Approval to Merck's Respiratory Syncytial Virus Vaccine for Infants
1 week ago /
Read about 0 minute
Author：小编
Merck has announced that the Food and Drug Administration (FDA) has approved its RSV vaccine, Enflonsia, specifically designed to safeguard infants from respiratory syncytial virus (RSV) infection during their inaugural infection season. Orders for the vaccine are anticipated to commence in July, ensuring its availability well before the virus begins to spread widely.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
